ME Therapeutics Holdings Inc.
METX
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.87% | -79.96% | 36.24% | 3.86% | 37.39% |
| Total Depreciation and Amortization | 6.01% | 27.97% | 88.16% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.50% | -84.21% | -86.55% | -9.46% | -44.56% |
| Change in Net Operating Assets | 9.15% | 223.12% | -380.56% | -9.09% | -119.47% |
| Cash from Operations | 4.94% | -29.90% | -36.99% | 3.65% | -4.58% |
| Capital Expenditure | -424.19% | 94.24% | -1,581.25% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Investing | 31.00% | 56.23% | -652.45% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -201.85% | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.59% | -101.61% | 18,157.50% | 27.27% | -101.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.56% | -152.53% | 478.87% | -7.64% | -151.13% |